The Role of Thoracic Radiation Therapy Dosing in the Treatment of Limited-Stage Small Cell Lung Cancer: A Study Based on the National Cancer Database

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2022 Apr 26

PMID 35469183

Authors

Chris Shidal

Evan C Osmundson

Yong Cui

Hyung-Suk Yoon

Christina E Bailey

Qiuyin Cai

Xiao-Ou Shu

Affiliations

Soon will be listed here.

Abstract

Purpose: Small cell lung cancer (SCLC) is a highly fatal disease, but its treatment has remained relatively unchanged for decades. Randomized clinical trials evaluating radiation therapy (RT) dosing and fractionation have yielded mixed results on overall survival (OS).

Methods And Materials: We identified 2261 patients with limited-stage (LS) SCLC undergoing definitive RT at 1.5, 1.8, and 2.0 Gy dose per fraction, concurrently with chemotherapy, between 2004 and 2015 within the National Cancer Database. Overall survival (OS) was evaluated using the Kaplan-Meier method, and Cox proportional hazards regression was used to investigate whether there was any survival difference among patients who received hyperfractionated, twice-daily RT at 1.5 Gy per fraction (HF1.5) and once-daily, standard fractionation RT at 1.8 Gy (SF1.8) or 2.0 Gy (SF2.0) per fraction. Subgroup analyses by age, sex, race, time to RT, facility type, and Charlson comorbidity index were also performed.

Results: All stage median OS rates for HF1.5, SF1.8, and SF2.0 Gy groups were 21.6, 18.9, and 19.4 months, respectively (log-rank = .0079). Multivariate analyses adjusting for demographic factors, socioeconomic status, tumor characteristics, and year of diagnosis showed SF1.8 (hazard ratio [HR] = 1.30, 1.03-1.63) and SF2.0 (HR = 1.20, 1.00-1.45) was associated with worse 1-year survival compared with HF1.5. This association was more evident in stage IIb-stage III than stage I to stage IIa patients. Propensity score-weighted analysis showed similar results. Stratified analyses showed the significant associations were confined to male or black patients, those aged >65 years, with 1 comorbidity, who had waited >60 days to start RT or were treated at an academic medical center.

Conclusions: Analyses of real-world treatment outcome data showed that receiving hyperfractionated, twice-daily RT was associated with improved survival among patients with LS-SCLC compared with standard, once-daily fractionation regimens at 1 year after diagnosis, particularly for subsets of patients. Some associations retained statistical significance 3 years postdiagnosis.

References

Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A . Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated?. Cancer. 2010; 116(5):1350-7. DOI: 10.1002/cncr.24853. View

Salama J, Hodgson L, Pang H, Urbanic J, Blackstock A, Schild S . A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013; 8(8):1043-9. PMC: 3822578. DOI: 10.1097/JTO.0b013e318293d8a4. View

De Ruysscher D, Lueza B, Le Pechoux C, Johnson D, OBrien M, Murray N . Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016; 27(10):1818-28. PMC: 5035783. DOI: 10.1093/annonc/mdw263. View

Turrisi 3rd A, Kim K, Blum R, Sause W, Livingston R, Komaki R . Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340(4):265-71. DOI: 10.1056/NEJM199901283400403. View

Combs S, Hancock J, Boffa D, Decker R, Detterbeck F, Kim A . Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol. 2014; 10(2):316-23. DOI: 10.1097/JTO.0000000000000402. View

Bogart J, Herndon 2nd J, Lyss A, Watson D, Miller A, Lee M . 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004; 59(2):460-8. DOI: 10.1016/j.ijrobp.2003.10.021. View

Micke P, Faldum A, Metz T, Beeh K, Bittinger F, Buhl R . Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?. Lung Cancer. 2002; 37(3):271-6. DOI: 10.1016/s0169-5002(02)00072-7. View

Choi N, Herndon 2nd J, Rosenman J, Carey R, Chung C, Bernard S . Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998; 16(11):3528-36. DOI: 10.1200/JCO.1998.16.11.3528. View

Fried D, Morris D, Poole C, Rosenman J, Halle J, Detterbeck F . Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22(23):4837-45. DOI: 10.1200/JCO.2004.01.178. View

10.

Resio B, Hoag J, Chiu A, Monsalve A, Dhanasopon A, Boffa D . Prophylactic cranial irradiation is associated with improved survival following resection for limited stage small cell lung cancer. J Thorac Dis. 2019; 11(3):811-818. PMC: 6462708. DOI: 10.21037/jtd.2019.01.64. View

11.

Pignon J, Arriagada R, Ihde D, Johnson D, Perry M, Souhami R . A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327(23):1618-24. DOI: 10.1056/NEJM199212033272302. View

12.

Pavan A, Attili I, Pasello G, Guarneri V, Conte P, Bonanno L . Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. J Immunother Cancer. 2019; 7(1):205. PMC: 6683488. DOI: 10.1186/s40425-019-0690-1. View

13.

Winchester D, Stewart A, Bura C, Jones R . The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2003; 85(1):1-3. DOI: 10.1002/jso.10320. View

14.

Varlotto J, Recht A, Flickinger J, Medford-Davis L, Dyer A, DeCamp M . Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. J Thorac Cardiovasc Surg. 2011; 142(3):538-46. DOI: 10.1016/j.jtcvs.2010.11.062. View

15.

Eberhardt W, Stamatis G, Stuschke M, Wilke H, Muller M, Kolks S . Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer. 1999; 81(7):1206-12. PMC: 2374330. DOI: 10.1038/sj.bjc.6690830. View

16.

Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two.... Lancet Oncol. 2015; 16(2):187-99. PMC: 4419359. DOI: 10.1016/S1470-2045(14)71207-0. View

17.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A . Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017; 18(8):1116-1125. PMC: 5555437. DOI: 10.1016/S1470-2045(17)30318-2. View

18.

Gronberg B, Killingberg K, Flotten O, Brustugun O, Hornslien K, Madebo T . High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021; 22(3):321-331. DOI: 10.1016/S1470-2045(20)30742-7. View

19.

Rutter C, Park H, Corso C, Yeboa D, Mancini B, Lester-Coll N . Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Lung Cancer. 2015; 90(2):243-8. DOI: 10.1016/j.lungcan.2015.08.002. View

20.

Oronsky B, Reid T, Oronsky A, Carter C . What's New in SCLC? A Review. Neoplasia. 2017; 19(10):842-847. PMC: 5596356. DOI: 10.1016/j.neo.2017.07.007. View